Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 118.02% | -- | -- | -- | -- |
| Gross Profit | -118.02% | -- | -- | -113.65% | -113.65% |
| SG&A Expenses | 27.14% | 13.67% | 17.57% | 43.48% | 18.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.23% | 3.44% | 10.97% | 22.83% | 25.34% |
| Operating Income | -2.23% | -3.44% | -10.97% | -155.63% | -223.08% |
| Income Before Tax | 5.70% | 25.47% | 22.17% | -117.16% | -54.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.70% | 25.47% | 22.17% | -117.16% | -54.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.70% | 25.47% | 22.17% | -117.16% | -54.62% |
| EBIT | -2.23% | -3.44% | -10.97% | -155.63% | -223.08% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 25.47% | 42.19% | 37.18% | -88.07% | -37.61% |
| Normalized Basic EPS | 26.92% | 41.33% | 36.49% | -92.65% | -44.44% |
| EPS Diluted | 25.47% | 42.19% | 37.18% | -88.07% | -37.61% |
| Normalized Diluted EPS | 26.92% | 41.33% | 36.49% | -87.14% | -40.54% |
| Average Basic Shares Outstanding | 29.98% | 30.76% | 27.27% | 19.94% | 15.37% |
| Average Diluted Shares Outstanding | 29.98% | 30.76% | 27.27% | 18.71% | 14.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |